Published August 28, 2022 | Version v1
Dataset Restricted

Non-erythroid heme biosynthesis gene, ALAS1, up-regulation after hypomethylating agents predict better outcome in patients with myelodysplastic syndrome

Authors/Creators

  • 1. EDA hospital; I-Shou University

Description

Supplementary Figure: mRNA next generation sequence analysis. (A) mRNA expression of MDS patients treated with AZA. MDS001: MDS with early AZA treatment failure. MDS001_1: before AZA treatment; MDS001_2: under AZA treatment, with response; MDS001_3: AZA treatment failure with leukemia change. MDS002: AZA failure within 2 years. MDS002_1: before treatment; MDS002_2: under AZA treatment, with response. MDS003: long-term AZA treatment response; MDS001: MDS001-1+MDS001-2+MDS001-3. MDS002: MDS002-1 + MDS002-2. MDS003 is MDS003-1

Notes

the genes we selected are highlight.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.